TITLE

Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression

AUTHOR(S)
Wen Zeng; Fankai Meng; Zeming Liu; Xia Mao; Li Luo; Miao Zheng; Shuang Qin; Wenli Liu; Jianfeng Zhou; Hanying Sun; Lifang Huang
PUB. DATE
July 2014
SOURCE
International Journal of Clinical & Experimental Pathology;2014, Vol. 7 Issue 7, p4239
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
97436123

 

Related Articles

  • Multiple Myeloma: Cost-Effective Treatment Regimens Featured at Recent Oncology Meetings. Graham, Robyn // American Health & Drug Benefits;Apr/May2009 Supplement 5, Vol. 2 Issue 3, pS148 

    The management of multiple myeloma has evolved rapidly over the past 5 years, with the introduction of novel therapies and combination drug regimens that have demonstrated improved efficacy. The 5-year survival rate has increased as a result of these improved therapies, although the length of...

  • A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment. Liu, Aijun; Yang, Guangzhong; Geng, Chuanying; Wang, Huijuan; Li, Lihong; Li, Yanchen; Wu, Yin; Tian, Ying; Leng, Yun; Wang, Guorong; Gao, Wen; Chen, Wenming // Acta Haematologica;Mar2016, Vol. 135 Issue 3, p140 

    To analyze the effects of bortezomib on the prognosis of the newly diagnosed multiple myeloma patients with renal impairment, we assessed the outcomes of 134 multiple myeloma patients with renal impairment (serum creatinine ≥ 178 μmol/l) who were treated at Beijing Chaoyang Hospital....

  • Bortezomib and Liposomal Doxorubicin Are Highly Effective in Obtaining the Best Possible Response before Autologous Transplant for Multiple Myeloma. Buda, Gabriele; Orciuolo, Enrico; Galimberti, Sara; Cecconi, Nadia; Petrini, Mario // Acta Haematologica;Oct2009, Vol. 122 Issue 1, p39 

    The article presents the clinical outcome on the effective treatment in obtaining the best response in patients with multiple myeloma (MM) before undergoing autologous stem cell transplantation (ASCT). 58 patients with newly diagnosed MM requiring therapy from March 2006 to December 2008 were...

  • Clinical Impact of Bortezomib in Frontline Regimens for Patients with Multiple Myeloma. Manochakian, Rami; Miller, Kena C.; Chanan-Khan, Asher A. // Oncologist;Aug2007, Vol. 12 Issue 8, p978 

    Standard frontline therapy for multiple myeloma comprises cytoreductive therapy with or without consolidative high-dose therapy plus stem cell transplantation (HDTSCT). Despite therapeutic advances, the disease remains incurable; most patients relapse following frontline treatment and die within...

  • Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens. Manier, S; Barthelemy, M; Fouquet, G; Prod'homme, C; Le Ray, E; Samarcq, P; Noel, M P; Terriou, L; Facon, T; Cossment, C; Boulanger, F; Leleu, X // Leukemia (08876924);Dec2012, Vol. 26 Issue 12, p2552 

    The article presents a retrospective study on newly-diagnosed multiple myeloma (MM) patients at the Apheresis Department, Etablissement Français du Sang (EFS) Nord de France. The study aims to prove that bortezomib-based induction regimens alter mobilization of stem cells and collection of...

  • Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma. Fostier, Karel; Becker, Ann De; Schots, Rik // OncoTargets & Therapy;2012 Part 2, Vol. 5, p237 

    Carfilzomib is a second-generation proteasome inhibitor with well-documented clinical activity as a single agent in patients with relapsed/refractory multiple myeloma. Carfilzomib can partially overcome resistance in bortezomib-refractory patients and has significant efficacy in...

  • Induction, maintenance bortezomib improved survival in newly diagnosed multiple myeloma. Leiser, Mark; Southall, Jennifer; Stott, Bob; Todak, Alexandra // Hem/Onc Today;2/10/2014, Vol. 15 Issue 3, p33 

    The article discusses the findings of a study in which a treatment regimen consisting of induction doxorubicin and dexamethasone plus bortezomib, followed by maintenance bortezomib, was able to improve response rates and survival outcomes in patients with newly-diagnosed multiple myeloma.

  • The Changing Treatment Paradigm in Patients With Newly Diagnosed Multiple Myeloma: Implications for Nursing. Tariman, Joseph D.; Estrella, Stella Marie // Oncology Nursing Forum;Nov2005, Vol. 32 Issue 6, pE127 

    Purpose/Objectives: To review the changing treatment paradigm for newly diagnosed multiple myeloma and its implications for nursing. Data Sources: Journal articles, textbooks, published research data. Data Synthesis: The treatment approaches to newly diagnosed multiple myeloma are varied, and no...

  • The Changing Treatment Paradigm in Patients With Newly Diagnosed Multiple Myeloma: Implications for Nursing. Tariman, Joseph D.; Estrella, Stella Marie // Oncology Nursing Forum;Nov2005 Supplement 2, Vol. 32, p127 

    Purpose/Objectives: To review the changing treatment paradigm for newly diagnosed multiple myeloma and its implications for nursing. Data Sources: Journal articles, textbooks, published research data. Data Synthesis: The treatment approaches to newly diagnosed multiple myeloma are varied, and no...

  • The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma. Dimopoulos, M A; Roussou, M; Gkotzamanidou, M; Nikitas, N; Psimenou, E; Mparmparoussi, D; Matsouka, C; Spyropoulou-Vlachou, M; Terpos, E; Kastritis, E // Leukemia (08876924);Feb2013, Vol. 27 Issue 2, p423 

    The role of thalidomide, bortezomib and lenalidomide in multiple myeloma patients presenting with renal impairment was evaluated in 133 consecutive newly diagnosed patients who were treated with a novel agent-based regimen. A significant improvement of renal function (renalPR (renal...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics